Death (before hospital discharge) or BPD (supplemental oxygen/respiratory support at 36 weeks' postmenstrual age if born < 32 weeks' gestation, or 28 days if born ≥ 32 weeks' gestation) · preterm infants requiring primary respiratory support
Nasal high flow showed no clear difference in death (before hospital discharge) or BPD(supplemental… compared with continuous positive airway pressure (low certainty).
1 finding from 1 review
Mortality before hospital discharge · preterm infants requiring primary respiratory support
Nasal high flow showed no clear difference in death (before hospital discharge) compared with continuous positive airway pressure (low certainty).
1 finding from 1 review
BPD (supplemental oxygen/respiratory support at 36 weeks' postmenstrual age if born < 32 weeks' gestation, or 28 days if born ≥ 32 weeks' gestation) · preterm infants requiring primary respiratory support
Nasal high flow showed no clear difference in BPD (supplemental oxygen/respiratory support at 36 weeks'… compared with continuous positive airway pressure (low certainty).
1 finding from 1 review
Treatment failure within 72 hours of trial entry · preterm infants requiring primary respiratory support
Nasal high flow probably leads to higher treatment failure within 72 hours of trial entry compared with continuous positive airway pressure (moderate certainty).
1 finding from 1 review
Mechanical ventilation within 72 hours of trial entry · preterm infants requiring primary respiratory support
Nasal high flow showed no clear difference in mechanical ventilation within 72 hours of trial entry compared with continuous positive airway pressure (moderate certainty).
1 finding from 1 review
Pneumothorax · preterm infants requiring primary respiratory support
Nasal high flow showed no clear difference in pneumothorax (during assigned treatment) compared with continuous positive airway pressure (moderate certainty).
1 finding from 1 review
Nasal trauma (during assigned treatment) · preterm infants requiring primary respiratory support
Nasal high flow probably leads to lower nasal trauma (during assigned treatment) compared with continuous positive airway pressure (moderate certainty).
1 finding from 1 review
Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or cerebral palsy at 1 to 3 years compared with continuous tapered dexamethasone regimen (moderate certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with continuous tapered dexamethasone regimen (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with continuous tapered dexamethasone regimen (low certainty).
1 finding from 1 review
Death · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Treatment failure · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes treatment failure compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Chronic lung disease · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
ICU length of stay (general intensive care patients) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events ‐ nasal trauma · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ nasal trauma compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Adverse events ‐ abdominal overdistention · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ abdominal overdistention compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Length of stay (days) (CL from birth) · preterm or low birth weight infants undergoing hospital care
1 finding from 1 review